- Home
- EM vs CHRS Comparison
EM vs CHRS Comparison
Compare EM & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EM | CHRS |
|---|---|---|
| Founded | 2017 | 2010 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 339.8M | 186.0M |
| IPO Year | 2021 | 2014 |
Fundamental Metrics
Financial Performance| Metric | EM | CHRS |
|---|---|---|
| Price | $1.19 | $1.38 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $1.25 | ★ $4.02 |
| AVG Volume (30 Days) | 936.7K | ★ 959.3K |
| Earning Date | 11-26-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 1.34 |
| Revenue | $259,541,587.00 | ★ $277,728,000.00 |
| Revenue This Year | $3.30 | N/A |
| Revenue Next Year | $5.26 | $67.29 |
| P/E Ratio | ★ N/A | $2.58 |
| Revenue Growth | N/A | ★ 152.07 |
| 52 Week Low | $0.68 | $0.71 |
| 52 Week High | $1.46 | $1.89 |
Technical Indicators
Market Signals| Indicator | EM | CHRS |
|---|---|---|
| Relative Strength Index (RSI) | 23.06 | 53.23 |
| Support Level | $1.33 | $1.31 |
| Resistance Level | $1.36 | $1.41 |
| Average True Range (ATR) | 0.05 | 0.09 |
| MACD | -0.02 | 0.02 |
| Stochastic Oscillator | 10.00 | 77.34 |
Price Performance
Historical ComparisonAbout EM Smart Share Global Limited
Smart Share Global Ltd is a consumer tech company providing mobile device charging services through an extensive online and offline network in China. It provides service through power banks, placed in POIs operated by location partners, such as entertainment venues, restaurants, shopping centers, hotels, transportation hubs, and public spaces. Geographically, the company generates revenue from the PRC. The company has two segments, the mobile device charging segment and the PV business segment. The company generates the majority of its revenue from the mobile device charging segment.
About CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.